Start here if you're new
what it is
INNOVATE runs construction, life sciences, and broadcast businesses in the U.S.
how it gets paid
Last year Innovate made $1.1B in revenue. Infrastructure construction was the main engine at $0.35B, or 35% of sales.
what just happened
Do not confuse nine months with one quarter: Q3 2025 revenue was $347.1M; diluted EPS was $(0.71). The $(4.27) figure is nine-month diluted EPS in the same exhibit.
At a glance
C balance sheet — red flag territory — real financial stress
20/100 earnings predictability — expect surprises
0.8% return on capital — nothing to write home about
-$3.08 fy2024 eps est
$1B fy2024 rev est
xvary composite: 25/100 — weak
What they do
INNOVATE runs construction, life sciences, and broadcast businesses in the U.S.
You are buying three businesses in one ticker. That is useful when one line sags and another still sells. The company has 3,065 employees, so this is not a tiny shop. operating margin → money left after direct costs and overhead → 5.8% means the core business is thin. return on capital → profit earned on invested money → 0.8% says each dollar tied up in the business barely works.
How they make money
$863.3M
nine months ended Sep 30, 2025 — consolidated (exhibit table)
Infrastructure (9M 2025)
$836.4M
largest line
Life sciences (9M 2025)
$9.4M
Spectrum (9M 2025)
$17.5M
The products that matter
industrial construction and steel
Infrastructure (DBM Global)
$338.4M Q3 2025 · ~$1.6B adjusted backlog
DBM Global is almost the entire consolidated top line. Q3 revenue was $338.4M in the Nov 12, 2025 release; nine-month infrastructure revenue was $836.4M of $863.3M consolidated.
core segment
biopharma r&d and services
Life Sciences
$3.1M Q3 2025 revenue (R2 line)
Life sciences remain small versus DBM; Q3 segment revenue was $3.1M in the release, with MediBeacon and R2 carrying the narrative more than the dollars.
subscale
wireless spectrum licensing
Spectrum
about $50M · pending $100M sale
This matters less as an operating segment than as a source of cash. The pending $100M ArcBest deal is relevant because it could help address $139M of long-term debt.
liquidity lever
Key numbers
$1.0B
FY2024 revenue
Revenue means sales. $1.0B in sales against a $58M market cap means the market is pricing in a lot of pain.
-$3.08
FY2024 EPS
EPS means profit per share. Negative $3.08 means the company lost money for each share.
5.8%
operating margin
Operating margin means profit before interest and taxes. 5.8% means the business keeps 6 cents of each dollar before financing costs.
$139M
long-term debt
Debt means borrowed money. $139M is heavy next to a $58M market cap.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $139M (71% of capital)
P0: INNOVATE Q3 2025 results — SEC exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/1006837/000100683725000126/exhibit991-q32025pressrele.htm
Total return vs. market
Return history isn't available for VATE right now.
source: institutional data · return history unavailable
What just happened
filed quarter
Q3 2025 consolidated revenue $347.1M (+43% YoY); diluted EPS $(0.71) vs. $(1.18) prior-year quarter.
Nine-month 2025 revenue was $863.3M (slightly below $870.5M in the same period of 2024). Nine-month diluted EPS was $(4.27) — that is a YTD figure, not the quarterly EPS.
$347.1M
Q3 revenue
$(0.71)
Q3 diluted EPS
$863.3M
9M 2025 revenue
context from the same release
DBM Global posted $338.4M of Q3 revenue; adjusted backlog was about $1.6B. Refinancing milestones also triggered disclosed strategic processes — read the full exhibit, not just the headline table.
P0: SEC exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/1006837/000100683725000126/exhibit991-q32025pressrele.htm
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk here is the construction backlog failing to convert into cash fast enough to support a debt-heavy balance sheet.
med
persistent net losses
A -6.35% net margin on $1.1B of revenue means roughly $70M in annual losses. That is not a one-line accounting nuisance. It is the core reason the equity looks distressed.
Impact: continued losses erode flexibility and keep equity holders dependent on financing or asset sales.
med
debt outruns the equity cushion
Long-term debt is $139M, or 71% of capital, against a market cap of about $58M. In human terms: creditors have a bigger claim on the story than shareholders do.
Impact: refinancing pressure or weaker operating results could hit the equity hard before the debt structure budges.
med
spectrum sale uncertainty
The pending $100M ArcBest transaction is a major liquidity event relative to this company's size. If it slips, shrinks, or fails, one of the clearest debt-reduction paths disappears.
Impact: liquidity stays tight and the turnaround has less room to absorb operational misses.
med
backlog quality becomes the whole story
The adjusted project backlog is $1.6B, which sounds comforting until you realize it is carrying most of the thesis. If project timing, execution, or margins disappoint, there is no second engine waiting behind it.
Impact: weaker backlog conversion would pressure revenue visibility and make the balance sheet look worse, not better.
At roughly $70M of annual net losses, even a large $1.6B backlog does not solve the problem by itself. The business has to convert work into cash while debt still sits at $139M.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
Next 10-K / Q4 2025 filing
Update FY2024–FY2025 loss figures and debt stack when the annual report posts — do not rely on stale FY2024 EPS stubs if the capital structure has been refinanced.
trend
backlog staying above $1.6B
That adjusted backlog is the support beam for the revenue story. A noticeable drop would tell you future work is thinning before the income statement improves.
metric
net margin versus the current -6.35%
The company does not need perfection first. It needs the loss rate to stop living in the mid-single-digit negative range on a percentage basis.
risk
closing the pending $100M spectrum deal
For a company with $139M of long-term debt and a $58M market cap, this is not side news. It is one of the clearest near-term balance-sheet catalysts.
Analyst rankings
earnings predictability
20 / 100
Low predictability means the quarterly numbers can swing around. In human-speak, analysts do not trust this business to print steady results.
risk rank
5
Safer than 5% of stocks means riskier than about 95% of them. That is what a stressed small cap looks like in the data.
price stability
5 / 100
The stock does not trade like a quiet value name. Expect volatility because the capital structure and operating results both need convincing.
source: institutional data
Institutional activity
institutional ownership data for VATE is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive